Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Progressive Multifocal Leukoencephalopathy
The effects of massage therapy on multiple sclerosis patients' quality of life and leg function.
Multiple sclerosis and oligodendroglioma: an exceptional association.
Cortical lesion load associates with progression of disability in multiple sclerosis.
Pharmaceutical approval update.
CLARITY – Safety and Efficacy of Oral Cladribine in Subjects with Relapsing-remitting Multiple Sclerosis (MS)
Leber's hereditary optic neuropathy associated with multiple sclerosis: Harding's syndrome.
Santhera enters agreement with Columbia University to investigate additional potential of Catena® in MELAS
Tumefactive multiple sclerosis lesions under fingolimod treatment.
CHMP assessment report for Sovrima (International nonproprietary name: idebenone)
Teva Announces Approval of Three-Times-A-Week COPAXONE® 40 mg/mL in Russia for the Treatment of Relapsing-Remitting Multiple Sclerosis
Effects of natalizumab treatment on the CSF proteome of multiple sclerosis patients.
Treatment selection and experience in multiple sclerosis: survey of neurologists.
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
Genmab announces details of planned ofatumumab Phase II study in multiple sclerosis
Parent-of-origin effect in multiple sclerosis: observations in half-siblings.
Rituximab induces clonal expansion of IgG memory B-cells in patients with inflammatory central nervous system demyelination.
Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone
Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial.
Narcolepsy with cataplexy and comorbid immunopathological diseases.
Targeting insulin-like growth factor 1 leads to amelioration of inflammatory demyelinating disease.
Vinpocetine inhibits oligodendroglial precursor cell differentiation.
Celiac disease and multiple sclerosis in the northwest of Iran.
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1R ) and receptor-5 (S1P5R ) agonist with autoimmune disease-modifying activity.

Pages